Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results
Presented Preliminary Clinical Data on RX-3117 in Bladder Cancer at the American Society of Clinical Oncologists (ASCO) Annual Meeting Strengthened Financial Position with a $10 million Registered Direct Offering ROCKVILLE, Md., Aug. 07, 2017 (GLOBE …